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Introduction
Functional dyspepsia (FD) is a common clinical syndrome consisting of recurrent or persistent abdominal symptoms of epigastric pain and fullness, early satiety, nausea, and/or vomiting in the absence of an organic cause. 1, 2 The pathophysiology of functional dyspepsia remains unclear, and many researchers have focused upon the following factors: gastric motor function, visceral sensitivity, Helicobacter pylori infection, and psychosocial factors. Among these, motility abnormalities of the stomach and upper small bowel have been found in the majority of patients with unexplained dyspepsia. 2 Understanding on the control of gastrointestinal (GI) motility was greatly improved by the discovery that a specialized cell type, the interstitial cell of Cajal (ICC), is also required for coordinated motility. [3] [4] [5] [6] The ICC is an electrically active cell and generates the slow waves which play an important role in gastric motility. 3, 4 In ICC and intestinal smooth muscle cells, there are sodium channel α-subunit gene (SCN5A) encoded sodium channels as well as KCNH2-encoded HERG potassium channels, which are associated with congenital long QT syndrome. It has been reported that there is no association between KCNH2 genotype status and GI symptoms, whereas patients with mutations in SCN5A have a higher prevalence of GI symptoms. 7 The sodium channel encoded by SCN5A has been described in human intestinal ICC and smooth muscle cells. [8] [9] [10] [11] In these studies, it was revealed that sodium flux through the sodium channel regulates membrane potential and slow-wave frequency, suggesting that the channel may participate in the regulation of GI motility. SCN5A also encodes the cardiac sodium channel responsible for the rapid depolarization of the cardiac action potential, and Brugada syndrome has been reported to be related to mutation of this gene ( Figure) . 12 Therefore, we hypothesized that mutation of the SCN5A gene may lead to abnormalities of gastric myoelectrical activity in patients with Brugada syndrome. To test this hypothesis, we measured an electrogastrography (EGG) for detection of gastric myoelectrical activities and collected dyspeptic symptom questionnaires from patients with Brugada syndrome and functional dyspepsia. Additionally, we evaluated FD patients without Brugada syndrome in the same methods for comparison.
M aterials and M ethods

Subjects and Clinical Data
Patients with Brugada syndrome were recruited from the Yonsei Cardiovascular Genome Center from June 2008 to November 2010. Patients with FD were recruited from Gangnam Severance Hospital over the same period. The protocol for this study was approved by Yonsei Medical Center Institutional Review Committee (3-2008-0066) in compliance with the Declaration of Helsinki, and the study was carried out under its guidelines. Informed consent was obtained from all participants.
The diagnosis of Brugada syndrome was based on a 12-lead ECG with the following ECG parameters: (1) at least a 2 mm ST-segment elevation in more than one right precordial lead (V1 to V3) with a right bundle branch block morphology and (2) a J-wave elevation ＞ 0.2 mV at baseline. The absence of a structural abnormality was confirmed by echocardiography. Patients confirmed Brugada syndrome received FD questionnaires, esphagogastoduodenoscopy, and genetic analysis of SCN5A from peripheral blood.
The diagnosis of FD was based on esophagogastroduodenoscopy and FD questionnaires. Participants diagnosed with FD were enrolled, and they were checked by ECG to exclude incidental co-morbidity of Brugada syndrome. Enrolled patients received EGG and genetic analysis of SCN5A from peripheral blood.
Questionnaires for Functional Dyspepsia
FD was diagnosed according to Rome-III criteria. Symptoms of epigastric pain, epigastric burning, postprandial fullness, early satiety, postprandial bloating and postprandial nausea or excessive belching were scored in accordance with the following scheme: 0 = none, 1 = mild (symptom could be ignored if the patient did not think about it), 2 = moderate (symptom could not be ignored but did not influence daily activities) and 3 = severe (symptom influenced daily activities). Symptom severity scores were added (minimum: zero to maximum 18). The frequency of dyspeptic symptoms described above was scored in accordance with the following scheme: 0 = none, 1 = once or twice in one month, 2 = once or twice in one week and 3 = above 3 times in a week. Scores were added (minimum: zero to maximum 18). Patients with FD were classified into 2 subtypes, PDS and EPS.
Electrogastrography
An ambulatory EGG (Digitrapper EGG, Synetics Medical Inc., Stockholm, Sweden) with active electrodes was used to record gastric myoelectrical activity. EGG was recorded in the morning after an overnight fast. To reduce the resistance between electrode and skin, conduction cream (Signa Creme Ⓡ , Parker Laboratories, Fairfield, NJ, USA) was applied to the skin after shaving the hair on the abdomen and performing abrasion with skin prepping paste (Omni Prep Ⓡ , DO Weaver & Co., Aurora, CO, USA). One active recording electrode was placed in the ventral midline halfway between the xiphoid process and umbilicus, a second active recoding electrode was placed 6 cm to the left of the first electrode, 45 o cephalad, and a third reference electrode was placed to the right of the first electrode. The 3 electrodes were connected to the Digitrapper EGG recording device. EGG of the preprandial period was recorded for 30 minutes before a meal, and EGG of the postprandial period was recorded for 30 minutes after a meal, with the patient in a sitting position, reclining at a 45 o angle in a comfortable chair. Solid meals (rice rolled up in dried seaweed with orange juice) were given to patients. All recording data were uploaded into a personal computer and analyzed by a software program (Polygram for Windows version 6.40, Synetics Medical Inc., Stockholm, Sweden). EGG recording data were analyzed according to the following parameters: (1) 
Genetic Analysis of SCN5A
The mutation analysis was carried out by polymerase chain reaction (PCR) followed by direct sequencing. Genomic DNA was extracted from peripheral blood leukocytes using QIAamp Ⓡ DNA blood kits (Qiagen, Valencia, CA, USA). The PCR was performed using modified primers to sites located in the intronic sequences and amplification conditions as previously described. 14 The amplified products were purified using QIAquick Ⓡ PCR purification kits (Qiagen) and directly sequenced using ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kits and an ABI PRISM 3730xl DNA analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were compared with the reference genomic and cDNA sequences of SCN5A (GenBank accession numbers NT 022517.17 and AY148488.1, respectively) using BLASTN.
Statistical Methods
Questionnaire scores and parameters recorded by EGG were statistically analyzed by the Mann-Whitney U test and Fisher's exact test using SPSS 17.0. A P-value of less than 0.05 was considered significant. 
Results
Patient Characteristics
Four patients with Brugada syndrome were enrolled in this study (Table 1) . Of 4 patients with Brugada syndrome, 3 were male and 1 was female. Their ages were between 29 and 59 years. SCN5A mutation was found in 3 patients (75%), one of whom met diagnostic criteria for a postprandial distress syndrome (PDS) subtype of FD.
Thirteen patients with FD were enrolled ( Table 1) . Four were male and 9 were female. Their ages were between 20 and 69 years. Nine patients had a PDS subtype and 4 had a EPS subtype. SCN5A mutation was found in only 1 patient with a PDS subtype of FD (7.7%).
Of 4 patients with SCN5A mutation, 2 (50%) had FD with a PDS subtype.
The severity and frequency of symptom scores are described in Table 1 . Since number of patients was small, we could not find specific symptom patterns according to mutation of SCN5A in Journal of Neurogastroenterology and Motility 
Electrogastrography Parameters
The EGG results of each patient are described in Table 2 . Four patients (3 Brugada syndrome and 1 FD) had SCN5A mutation in our study. Case 1 (No. 1) was a 29-year-old male who had Brugada syndrome associated with the PDS subgroup of FD. Power ratio (PR) at 3 cycle/min was 1.0. In the preprandial period, most of the frequency was in the normal range (90.9%). However, in the postprandial period, the dominant frequency changed to bradygastria (75%). Case 2 (No. 2) was a 49-year-old male with Brugada syndrome without GI symptoms. PR at 3 cycle/min was 4.0, and 85.7% of the waves were in the 2-4 cycle/min range in the preprandial period. However, he had postprandial tachygastria (33.3%). Case 3 (No. 3) was a 58-year-old female who has Brugada syndrome without FD, but PR at 3 cycle/min was decreased to 0.4. She had normal slow waves (85.2%) in the preprandial period, and tachygastria (33.3%) in the postprandial period. Case 4 (No. 5) was a 58-year-old female who had a PDS subtype of FD without Brugada syndrome. PR at 3 cycle/min was decreased to 0.2, but the dominant frequency was in the normal range in the pre-prandial (71.4%) and post-prandial (87.5%) periods, respectively.
Postprandial tachygastria and bradygastria were noted in 2 (50%) and 1 (25%) of 4 patients with SCN5A mutation, respectively.
In the SCN5A mutation negative group (12 FD and 1 Brugada syndrome), 2 patients were bradygastric (15.4%), 5 patients were normal (38.4%) and 6 patients were tachygastric (46.2%) in the preprandial period. In addition, 2 patients were bradygastric (15.4%), 10 patients were normal (76.9%) and 1 patient was tachygastric (7.7%) in the postprandial period. Seven patients (53.8%) showed decreased postprandial PR.
However, the EGG parameters were not significantly different depending on SCN5A mutation (Table 3) .
Discussion
The hypothesis of our study was that mutation in the SCN5A gene may be related to dyspeptic symptoms and abnormalities of gastric myoelectrical activity in patients with Brugada syndrome and/or FD. Due to the limited number of patients in our study, we could not obtain significant differences in symptoms and/or EGG parameters depending on SCN5A mutation.
SCN5A encodes the molecular identity of the pore-forming α -subunit of the tetrodotoxin-insensitive sodium channel in both human intestinal smooth muscle and cardiac myocytes. 11 The role of a sodium channel is less well defined in smooth muscle and ICC of the GI tract. There is a report, however, that a mechanosensitive sodium current present in human intestinal ICC may play an important role in the normal physiological control of human intestinal motor function by contributing to the setting of the membrane potential, the rate of rise of the slow wave, and mechanosensitive regulation of slow wave frequency. 11 The electrical slow wave is generated from ICC. Blockers of the sodium current slow the rate of rise and decrease the frequency of the slow wave, while stretching of human circular smooth muscle strips for activation of the mechano-sensitive sodium channel which increases the frequency of the slow wave.
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Mutations in SCN5A that affect the electrical phenotype of the Na V 1.5 channel may therefore alter the contribution of the sodium channel to the intrinsic electrical activity of the intestine and may result in abnormal intestinal motility. 7 In other words, GI phasic mechanical contractions are preceded by changes in the electrical activity of smooth muscle cells. It is a well-known fact that mutations in the SCN5A gene have been linked to a variety of diseases causing sudden cardiac death in cardiology. The sodium channel isoform Na V 1.5, encoded by the SCN5A gene, is the predominant α-subunit in the heart, and plays a key role in the excitability of atrial and ventricular cardiomyocytes. Mutations in SCN5A that result in de-fined electrophysiological abnormalities can be divided into 2 primary arrhythmogenic phenotypes in the heart. 15 One is gain-offunction mutations to yield the LQT3 phenotype, 16 and the other is loss-of-function mutations resulting in the BrS1 phenotype. 17 One study reported that there is the possibility that both gainand loss-of-function mutations involving the sodium channel may increase susceptibility to GI symptoms. 7 They showed that subjects with an SCN5A mutation had more GI symptom complexes (OR 5.2; 95% CI, 1.5-18.3). 7 There is also a study that evaluated SCN5A as a candidate gene involved in the pathogenesis of irritable bowel syndrome (IBS). 18 These researchers recruited 49 subjects diagnosed with IBS and performed mutational analysis on their genomic DNA. They found that the G298S-SCN5A missense mutation caused a marked reduction of whole cell sodium current and loss of function of Na V 1.5, and suggested the concept of an intestinal channelopathy resulting in IBS. However, we did not find specific symptom patterns according to mutation of SCN5A in patients with Brugada syndrome and FD.
There are several reports that suggest a close relationship between dyspeptic symptoms and myoelectrical abnormalities including instability of the gastric pacemaker frequency, tachygastria in both the fasting and postprandial states, or the absence of the normal amplitude increase in the postprandial period. 19, 20 Therefore, we attempted to prove the possible relationship between SCN5A mutation and gut channelopathy by EGG analysis.
A limitation of our study is that the number of subjects was too small. Although our institution is a tertiary referral center, there were only a few dozen people who could participate in this study because of the extremely low prevalence of Brugada syndrome.
Although we did not find statistically significant results both in symptoms and EGG parameters, it is meaningful to attempt to identify differences in gastric myoelectric activity according to the presence of SCN5A mutation. In order to demonstrate channelopathy as one of the pathophysiologic mechanism of FD, a large-scale multi-center study is needed in the future.
